Saturday 10 October 2026 Export all IDXG data to Excel Powerpack

Interpace Biosciences, Inc.

IDXG

Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.

6.00 0.00 0.00%
Market cap
—
P/E
0.2×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
−6.95
Beneish M
2.07
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 5 5 6
ROE
(11.50%) 243.97% 210.21% 221.93%
ROA
25.58% 101.07% 98.74% 104.29%
ROIC
0.00% 12.85% 10.33% 12.67%
Return on Tangible Assets
70.57% 395.10% 323.25% 320.07%
Average Days of Receivables
51.95 53.24 59.67 63.73
Free Cash Flow per Share
4.42 5.68 0.98 0.74
Free Cash Flow
3.91 5.03 4.45 4.10
Other line items

Show all line items

Columns are period end dates · fundamentals updated 28 Sep 2026